Five biotech and pharma stocks to watch

FiercePharma's sister publication FierceBiotech asked prominent market analysts to weigh in on major biopharma milestones on the near horizon. So Dr. Simos Simeonidis, the senior biotech analyst for Rodman & Renshaw, scanned the radar for key upcoming events. He focuses on five biotech and pharma companies at important crossroads in their development. Their success or failure at this juncture will have a big impact on their future. Article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.